Pharming Group (NASDAQ:PHAR) Trading Up 6.2% – Should You Buy?

Shares of Pharming Group (NASDAQ:PHAR) rose 6.2% on Monday . The stock traded as high as $9.65 and last traded at $9.41. Approximately 2,319 shares were traded during trading, a decline of 61% from the average daily volume of 5,913 shares. The stock had previously closed at $8.86.

Wall Street Analysts Forecast Growth

PHAR has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a report on Tuesday, December 17th. Jefferies Financial Group started coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 price target on the stock.

Pharming Group Trading Up 0.3 %

The firm has a market capitalization of $622.48 million, a price-to-earnings ratio of -35.19 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The company has a 50 day moving average price of $9.36 and a two-hundred day moving average price of $8.52.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its holdings in Pharming Group (NASDAQ:PHAR) by 16.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent filing with the Securities & Exchange Commission. 0.03% of the stock is currently owned by institutional investors and hedge funds.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.